ReviewPostepy dermatologii i alergologii2014
Omalizumab in an allergology clinic: real life experience and future developments.
Review in Postepy dermatologii i alergologii, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- The Incredible Adventure of Omalizumab.International journal of molecular sciences · 2024Review
- Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study.Postepy dermatologii i alergologii · 2017Article
- Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.BMC pulmonary medicine · 2016Observational
- Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia.Postepy dermatologii i alergologii · 2015Article
- Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report.Postepy dermatologii i alergologii · 2014Article
- Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies.Postepy dermatologii i alergologii · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating IgE and expression of IgE high affinity receptor (FCɛRI) on mast cells and basophils. Its role in the therapy of allergic asthma and urticaria is well established. According to GINA guidelines, omalizumab should be considered as an important alternative to systemic corticosteroids in uncontrolled asthma. Several ongoing trials will evaluate omalizumab efficacy in the treatment of other allergic diseases and conditions. Further studies are needed to answer several practical questions on the optimal duration of treatment and possible biomarkers to predefine a cohort of responders to this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.